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Abstract
The heptavalent pneumococcal vaccine’s introduction resulted in
a decline in invasive disease caused by Streptococcus pneumoniae,
but was accompanied by an increase in non-vaccine serotypes.
We evaluated a modiﬁed scheme of the sequential multiplex
PCRs adapted to the prevalence of serotypes in Seville (Spain)
for determining capsular serotypes of S. pneumoniae invasive clin-
ical isolates. In adults, the modiﬁed scheme allowed us to type
73% with the ﬁrst three reactions, and 92% with two additional
PCRs. In paediatric patients, it allowed us to type 73.5% with
the ﬁrst three reactions, and 90% with the two additional PCRs.
The multiplex PCR approach was successfully adapted to target
the serotypes most prevalent in Seville.
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Streptococcus pneumoniae causes severe illnesses in the
elderly and children. The immunochemistry of the capsular
polysaccharide differentiates pneumococci into 91 distinct
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serotypes [1], but only approximately 15 serotypes cause the
majority of cases of invasive pneumococcal disease world-
wide [2,3].
The introduction of the heptavalent pneumococcal vaccine
resulted in a decline in invasive disease caused by S. pneumo-
niae in children and a signiﬁcant decline in the non-vaccinated
population, owing to a pronounced herd effect [4,5]. How-
ever, the overall decrease in the burden of pneumococcal
invasive disease was accompanied by an increase in the num-
ber of cases caused by non-vaccine serotypes. The situation
in countries where the vaccine is available but not universally
administered, such as Italy [6], Spain and Portugal, is even
more complex [7]. Depending on the fraction of vaccinated
children, one might expect a variable magnitude of reduction
in the infections caused by vaccine serotypes in the overall
paediatric population, and also the existence and amplitude
of indirect effects on infections in adults [7].
Serotype surveillance will continue to be necessary for
evaluation of the impact and suitability of current and future
multivalent vaccines [8]. Studies of serotype distribution rely
on conventional serotyping (the Quellung reaction) for direct
determination of serotypes. The expense and intrinsic techni-
cal difﬁculties of conventional serotyping limit its use to a
few highly specialized laboratories. Multiplex PCR-based
methods that speciﬁcally identify capsular serotype-speciﬁc
sequences offer a simple and economical approach for the
surveillance of pneumococcal disease [9]. In addition, the
development of PCR-based assays for direct detection of
select serotypes from clinical specimens could be a valuable
aid in surveillance, particularly in situations where culture is
insensitive [10–14]. Pai et al. [15] have developed a sequen-
tial multiplex PCR for deducing 28 serotypes, providing the
capability to perform surveillance of serotypes with basic
DNA ampliﬁcation and electrophoresis equipment (the CDC
has recently expanded the list of serotypes to 40; see http://
www.cdc.gov/ncidod/biotech/ﬁles/pcr-serotyping-clinical-speci
mens-May2009.pdf). This approach has been used to identify
the distribution of pneumococcal clinical isolate serotypes
from several countries [16–18].
We evaluated a modiﬁed scheme of the CDC sequential
multiplex PCRs for serotyping of S. pneumoniae invasive clini-
cal isolates from adults and paediatric patients. In this
method, the primer combinations used were adapted to the
serotype distribution in Seville (Spain). The pneumococci
were recovered at the Hospital Virgen Del Rocio (1031
beds, population coverage 875.331 habitants) in Seville. In
Spain, from 1979 to 2007, different therapeutic approaches
(antibiotics) and preventive measures (PCV7) were
introduced [19]. The increased prevalence of antibiotic non-
susceptibility and PCV7 serotypes that was associated with
antibiotic consumption in the 1980s and 1990s was reversed
in the 2000s, when vaccine dose distribution increased. At
the same time, non-PCV7 serotypes became more prevalent,
particularly serotypes 1 and 19A [19].
Two hundred and ﬁfty-seven isolates obtained from 2004
to 2008 in Seville were tested [15], including 102 previously
typed paediatric isolates, and 155 adult isolates, by serologi-
cal determination of capsular type. All of the isolates were
recovered from sterile ﬂuids: blood (215 isolates), cerebro-
spinal ﬂuid (30 isolates), pleural ﬂuid (ten isolates), and syno-
vial ﬂuid (two isolates).
The samples were cultured on Columbia Blood agar in 5%
CO2 at 37C, and the a-haemolytic colonies were tested for
optochin susceptibility and bile solubility, in order to identify
S. pneumoniae.
The published PCR protocol has seven sequential reac-
tions. We modiﬁed the order of primers proposed in order
to improve the efﬁciency of the original scheme for survey-
ing our geographical area. The main changes were that
primers for serotype 5 were included in PCR 3, and that
serotype 1 was changed from PCR 6 to PCR 3. DNA
extraction, PCRs and electrophoresis were performed as
described previously [15]. To resolve the highly homologous
serotypes 6A/C and 6B, we supplemented the multiplex
assay with sequencing [20]. After this, we differentiated sero-
types 6A and 6C with a PCR assay [21].
Concordance of the PCR with conventional serotyping
was 91% in the paediatric isolates. Three of the ﬁve isolates
for which serotypes could not be deduced were serotypes
not included in the reaction scheme. The multiplex PCR
typed 97.4% of adult isolates, and 93.1% of paediatric
isolates. Two isolates (1.3%) in adults and ﬁve isolates (4.9%)
in infants were not assigned serotypes. Two isolates in each
group (1.3% and 2%) failed to amplify the positive control.
Table 1 shows S. pneumoniae serotype determination using
our sequential PCR schemes for adult and paediatric
patients.
The ﬁrst three reactions allowed us to type 73% of adult
isolates, but this ﬁgure rose to 92% with two additional
PCRs; using the original scheme, we could type 63% and
74.8%, respectively. In the paediatric group, the ﬁrst three
reactions allowed us to type 73.5% vs. 60%, and the two
additional PCRs allowed us to type 90% vs. 72.5%. By
sequencing and PCR, we identiﬁed seven of the 22 sero-
type 6A/B/C isolates as serotype 6A, 11 as serotype 6B, and
three as serotype 6C. One isolate was not differentiated.
The CDC sequential multiplex PCRs for determining cap-
sular serotypes of S. pneumoniae offers a simple and econom-
ical approach and a good alternative to conventional
serotyping, and could be adapted to more efﬁciently detect
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predominant serotypes in regions outside the USA. Other
authors have adapted the original scheme to their serotype
prevalence, conﬁrming the ﬂexibility of the general method
by altering combinations of serotypes and showing that each
serotype-speciﬁc primer pair is speciﬁc for a given serotype,
regardless of strain diversity within different countries.
We evaluated a modiﬁed scheme adapted to the isolates
most prevalent in Seville (Spain). These modiﬁcations allowed
us to type 10% more adult isolates with the ﬁrst three reac-
tions and 13% more paediatric isolates. With ﬁve PCRs, we
typed 17% more isolates in both patient groups, serotyping
92% and 90%, respectively.
Serotypes 20 and 7C were included in the scheme, but
were not found among these isolates. Similarly, we had no
isolates of serotype 10, which was included in the original
scheme. We removed this serotype from the scheme
because of the incompatibility of size in the gels.
The multiplex PCR approach has been successfully
adapted to paediatric and adult invasive clinical isolates to
target the serotypes most prevalent in Seville and to identify
serotypes from more than 95% of the isolates tested. There-
fore, this schematic approach is particularly helpful in maxi-
mizing the detection of predominant types using a limited
number of multiplex reactions, and can be used in Seville as
an alternative to costly conventional serotyping.
The ability to determine prevalent pneumococcal capsular
serotypes is currently important for the introduction and post-
vaccine evaluation of new pneumococcal conjugate vaccines.
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patients (n = 102)
Cumulative
score (%)
PCR 1 36 (23.2) 36 (23.2) 30 (29.4) 30 (29.4)
19A 478 13 7
3 371 7 5
22F/(22A) 643 9 3
6A/B 250 7 15
PCR 2 48 (30.9) 84 (54.2) 24 (23.5) 54 (52.9)
4 430 7 0
14 208 17 15
12F/(12A) 376 10 0
7F/(7A) 826 14 9
PCR 3 29 (18.7) 113 (72.9) 21 (20.6) 75 (73.5)
1 280 13 18
16F 988 3 1
35F/(47F) 517 2 0
5 362 11 2
PCR 4 15 (9.7) 128 (82.5) 7 (6.9) 82 (84.4)
23F 384 1 2
9V/(9A) 753 6 1
11A/(11D) 463 4 3
8 294 4 1
PCR 5 15 (9.7) 143 (92.5) 10 (9.8) 92 (90.2)
19F 304 5 3
15A 436 6 0
18C/(18A,18B,18F) 573 2 6
35B 677 2 1
PCR 6 5 (3.2) 148 (95.5) 2 (1.9) 94 (92.2)
33F 338 3 1
15B/C 496 1 0
38/(25F) 574 1 0
31 701 0 1
PCR 7 3 (1.9) 151 (97.4) 1 (1.0) 95 (93.1)
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No ampliﬁcation 2 (1.3) 2 (2)
No serotyping 2 (1.3) 5 (4.9)
aCommon serotype combinations are indicated by a slash mark. Rare serotypes are in parentheses.
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